Three-drug attack on deadly pancreatic cancer tested in patients
NCT ID NCT01204372
Summary
This study tested whether combining three existing drugs could better control advanced pancreatic cancer that had spread. Sixty-three patients received gemcitabine by IV, trastuzumab by IV, and erlotinib as a daily pill. Researchers measured how well the combination stopped or slowed tumor growth and extended survival.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Val d'Aurelle
Montpellier, 34298, France
Conditions
Explore the condition pages connected to this study.